Table 1.
Summary of three randomized controlled trials included in the meta-analysis
| Study | Publication year | Stage | CT regimen | CRT regimen | Number of patients | Median survival | ||
|---|---|---|---|---|---|---|---|---|
| CT | CRT | CT | CRT | |||||
| Girard et al. | 2010 | cN2 IIIA | GC | VP or PC + Con RT(46Gy) | 14 | 32 | 24.2 | – |
| Katakami et al. | 2012 | pN2 IIIA | DC | DC + Con RT(40Gy) | 28 | 28 | 29.9 | 39.6 |
| Pless et al. | 2015 | pN2 IIIA | DP | DP + Seq RT(44Gy) | 115 | 117 | 26.2 | 31.7 |
Abbreviations: GC gemcitabine + cisplatin, DP docetaxel + cisplatin, DC docetaxel + carboplatin, VP vinorelbine + cisplatin, PC paclitaxel + carboplatin, Seq RT sequential radiochemotherapy, Con RT concomitant radiochemotherapy